Mens sana in corpore sano revisited by Jeger, Raban V.
EDITORIAL
Mens sana in corpore sano revisited
Raban V. Jeger*
Cardiology University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
Online publish-ahead-of-print 4 July 2013
This editorial refers to ‘The use of cholinesterase inhibitors
and the riskof myocardial infarction and death: a nationwide
cohort study in subjects with Alzheimer’s disease’†, by
P. Nordstro¨m et al., on page 2585
Orandum est ut sit mens sana in corpore sano.
Juvenal, Satire X
Acetylcholine is an important neurotransmitter for the central,
peripheral, and autonomic nervous systems of the human body. It is
synthesized in the presynaptic neuron by the enzyme choline acetyl-
transferase from choline and acetyl-coenzyme A. After its release
into the synaptic cleft, it binds to the acetylcholine receptors on
the postsynaptic membrane that trigger the intracellular response
(Figure 1). In the synaptic cleft, acetylcholine is hydrolysed by
the enzyme acetylcholinesterase in order to terminate synaptic
transmission.
Depending on the type of nervous system and the target tissue,
acetylcholine may act in numerous ways. While it activates skeletal
muscles via the peripheral nervous system, it exerts various effects
in the autonomic nerve system, specifically by sympathetic and
parasympathetic neurons. Originally discovered in 1921, acetylcho-
line is the main neurotransmitter in the parasympathetic nervous
system regulating internal organs and glands.1 Last but not least,
acetylcholine-dependent neurons act as the cholinergic system in
the central nervous system, with important effects on cognitive func-
tions specifically during waking and maintaining attention.
Patients with Alzheimer’s disease show less activity of the enzyme
choline acetyltransferase in the presynaptic neuron, which leads to a
decreased production of acetylcholine. Acetylcholinesterase inhibi-
tors (AChEIs) block the acetylcholinesterase in the synaptic cleft,
therefore inhibiting the breakdown of acetylcholine into acetate
and choline and prolonging its duration of action (Figure 1). Drugs
such as galantamine (e.g. Nivalinw or Razadynew), donepezil
(Ariceptw), and rivastigmine (Exelonw) arewidely used for the treat-
ment of dementia due to Alzheimer’s disease. Used in patients with
mild to moderate dementia, treatment with an AChEI over 6–12
months has been shown to improve cognitive function and activities
of daily living and behaviour.2 Side effects are mainly gastrointestinal,
and include nausea, vomiting, and diarrhoea. However, although
most drug effects take place in the central nervous system and the
gastrointestinal tract, AChEIs may also act in the cardiovascular
system due to the fact that the heart and vessels have a rich auto-
nomic innervation. Potentially adverse cardiovascular side effects
of AChEIs include hypertension and prolongation of the conduction
time in both the sinus and atrioventricular nodes, with resulting
bradycardia and reduced beat-to-beat fluctuations.3 AChEI therapy
is associatedwith increased rates of hospitalizations due to bradycar-
dia and syncope.4–6 However, data from randomized controlled
trials showno evidence for increased rates of adverse cardiovascular
side effects in patients treated with AChEIs.2 Since patients with de-
mentia usually suffer fromco-morbid conditions such as cardiovascu-
lar diseases, but most of them are not included in randomized
controlled trials because theyexhibit exclusion criteria,7 no clear evi-
dence exists on the cardiovascular side effects of AChEIs in a general
population with Alzheimer’s disease.8
Nordstro¨m et al. now report data from nationwide Swedish data-
bases, i.e. the SwedishDementia Registry, theNational Patient Regis-
ter, and theNationalRegister forPrescribedandExpeditedDrugs, on
the association on AChEI use and cardiovascular events.9 After ad-
justment for confounders, AChEI use was associated with lower
rates of myocardial infarction [hazard ratio (HR) 0.62, 95% confi-
dence interval (CI) 0.40–0.95] and death (HR 0.64, 95% CI 0.54–
0.76) among 7073 subjects with newly diagnosed dementia due to
Alzheimer’s disease between 2007 and 2010 over a mean follow-up
timeof 503days, an effect thatwas evenmorepronounced inpatients
taking the highest recommended AChEI dose. However, data on
bradycardia and syncope were not reported.
How can these results be put into perspective? Based on theoret-
ical considerations and results from previous population-based
studies, the use of AChEIs was associated with increased rather
than decreased cardiovascular event rates in a population with
Alzheimer’s disease, mainly due to cholinergic side effects with po-
tentially higher rates of bradycardia and syncope.4–6 However, the
opposite was true in the study of Nordstro¨m et al.,9 with a clearly
lower rate of myocardial infarction and death in patients treated
with AChEIs.What could be the possible mechanism for this appeal-
ing finding? Recently, a so-called cholinergic anti-inflammatory
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pathway was described, i.e. a mechanism of autonomic regulation of
local and systemic inflammation through the vagus nerve and its
major neurotransmitter, acetylcholine.10 Based on this paradigm, it
might be hypothesized that the modulation of inflammation in the
heart’s cholinergic system could influence degenerative processes
in the vascular bed. Therefore, AChEIs, due to their proposed anti-
inflammatory properties, might stabilize arteriosclerotic plaques
and hamper the development of acute coronary syndromes.
Other potential mechanisms such as a lower heart rate could lead
to a decreased cardiac output and lower oxygen demand, which
could also improve cardiovascular outcome. Finally, AChEIs may
interfere with local levels of acetylcholine in the vasculature since
acetylcholine stimulates the activity of the enzyme endothelial
nitric oxide synthase and the release of nitric oxide via muscarinic
receptors on endothelial cells. Previous data show that AChEI treat-
ment increases cerebral blood flow in patients with Alzheimer’s
disease and improves cognitive functions even in patients with
vascular dementia.11,12
What we hear is the tale of a drug that improves both cognitive
functions and cardiovascular health in a multimorbid population
with dementia. But is this credible? Based on current knowledge,
there is no clear evidence of whether AChEIs are beneficial or not
in terms of cardiovascular events in elderly andmultimorbid patients
with Alzheimer’s disease. Still additional large population-based
studies are needed to evaluate further the cardiovascular risk in
such a cardiovascular high-risk population. Since the study of Nord-
stro¨m et al. is purely observational, its results have to be interpreted
with caution and currently are hypothesis generating only. However,
if AChEI treatment is demonstrated to improve not only mental but
also physical health, theremight then be a case for a large randomized
outcome study in patients with coronary artery disease irrespective
of dementia.
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Figure 1 Acetylcholinesterase inhibitors (AChEIs) in cholinergic nerve transmission. Acetylcholine is produced in the presynaptic neuron by the
enzyme choline acetyltransferase from acetyl-coenzyme A and choline, and later released in the synaptic cleft where it binds to the acetylcholine
receptor on the postsynaptic membrane, triggering an intracellular response. The enzyme acetylcholinesterase hydrolyses acetylcholine into
acetate and choline in order to terminate synaptic transmission. Choline is transported into the presynaptic neuron by the choline carrier and
serves as a substrate for the described production of acetylcholine. AChEIs inhibit the enzyme acetylcholinesterase, which in turn inhibits the break-
down of acetylcholine into acetate and choline and prolongs its duration of action.
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